Unleashing the Power of Targeted Immunotherapies
for Cancer

About us

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win® technology platform.

Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Latest news

New publication: Durable clinical responses in stage III–IV non-small-cell lung cancer patients treated with IDO peptide vaccine in a phase I study

New publication: Durable clinical responses in stage III–IV non-small-cell lung cancer patients treated with IDO peptide vaccine in a phase I study